213 related articles for article (PubMed ID: 20942457)
1. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
Milane L; Duan Z; Amiji M
Mol Pharm; 2011 Feb; 8(1):185-203. PubMed ID: 20942457
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.
Milane L; Duan ZF; Amiji M
Nanomedicine; 2011 Aug; 7(4):435-44. PubMed ID: 21220050
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
Milane L; Duan Z; Amiji M
PLoS One; 2011; 6(9):e24075. PubMed ID: 21931642
[TBL] [Abstract][Full Text] [Related]
4. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment.
Zhang Y; Tang L; Sun L; Bao J; Song C; Huang L; Liu K; Tian Y; Tian G; Li Z; Sun H; Mei L
Acta Biomater; 2010 Jun; 6(6):2045-52. PubMed ID: 19969111
[TBL] [Abstract][Full Text] [Related]
5. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
[TBL] [Abstract][Full Text] [Related]
7. Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.
Cho H; Lai TC; Kwon GS
J Control Release; 2013 Feb; 166(1):1-9. PubMed ID: 23246471
[TBL] [Abstract][Full Text] [Related]
8. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.
Mattu C; Pabari RM; Boffito M; Sartori S; Ciardelli G; Ramtoola Z
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):463-72. PubMed ID: 23916461
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer.
Ren F; Chen R; Wang Y; Sun Y; Jiang Y; Li G
Pharm Res; 2011 Apr; 28(4):897-906. PubMed ID: 21184150
[TBL] [Abstract][Full Text] [Related]
11. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
12. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model.
van Vlerken LE; Duan Z; Little SR; Seiden MV; Amiji MM
Mol Pharm; 2008; 5(4):516-26. PubMed ID: 18616278
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Patil Y; Panyam J
Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
[TBL] [Abstract][Full Text] [Related]
15. Ligand-installed polymeric nanocarriers for combination chemotherapy of EGFR-positive ovarian cancer.
Xi X; Lei F; Gao K; Li J; Liu R; Karpf AR; Bronich TK
J Control Release; 2023 Aug; 360():872-887. PubMed ID: 37478915
[TBL] [Abstract][Full Text] [Related]
16. Degradable porous drug-loaded polymer scaffolds for localized cancer drug delivery and breast cell/tissue growth.
Obayemi JD; Jusu SM; Salifu AA; Ghahremani S; Tadesse M; Uzonwanne VO; Soboyejo WO
Mater Sci Eng C Mater Biol Appl; 2020 Jul; 112():110794. PubMed ID: 32409024
[TBL] [Abstract][Full Text] [Related]
17. Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response.
Tran BN; Nguyen HT; Kim JO; Yong CS; Nguyen CN
Drug Dev Ind Pharm; 2017 Dec; 43(12):1952-1962. PubMed ID: 28724314
[TBL] [Abstract][Full Text] [Related]
18. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
19. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.
van Vlerken LE; Duan Z; Seiden MV; Amiji MM
Cancer Res; 2007 May; 67(10):4843-50. PubMed ID: 17510414
[TBL] [Abstract][Full Text] [Related]
20. Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis.
Wang X; Beitler JJ; Wang H; Lee MJ; Huang W; Koenig L; Nannapaneni S; Amin AR; Bonner M; Shin HJ; Chen ZG; Arbiser JL; Shin DM
PLoS One; 2014; 9(2):e86369. PubMed ID: 24586249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
